Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142

1.

mTOR function in skeletal muscle hypertrophy: increased ribosomal RNA via cell cycle regulators.

Nader GA, McLoughlin TJ, Esser KA.

Am J Physiol Cell Physiol. 2005 Dec;289(6):C1457-65. Epub 2005 Aug 3.

2.

The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.

Mita MM, Mita A, Rowinsky EK.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S169-77. Review.

PMID:
14508096
3.

Skeletal myocyte hypertrophy requires mTOR kinase activity and S6K1.

Park IH, Erbay E, Nuzzi P, Chen J.

Exp Cell Res. 2005 Sep 10;309(1):211-9.

PMID:
15963500
4.

The hypertrophic response in C2C12 myoblasts recruits the G1 cell cycle machinery.

Hlaing M, Shen X, Dazin P, Bernstein HS.

J Biol Chem. 2002 Jun 28;277(26):23794-9. Epub 2002 Apr 19.

5.
7.

p18INK4c and p27KIP1 are required for cell cycle arrest of differentiated myotubes.

Myers TK, Andreuzza SE, Franklin DS.

Exp Cell Res. 2004 Nov 1;300(2):365-78.

PMID:
15475001
8.

Acute renal failure during sepsis: potential role of cell cycle regulation.

Yang QH, Liu DW, Long Y, Liu HZ, Chai WZ, Wang XT.

J Infect. 2009 Jun;58(6):459-64. doi: 10.1016/j.jinf.2009.04.003. Epub 2009 Apr 17.

PMID:
19428114
9.
10.

Mammalian target of rapamycin inhibitors rapamycin and RAD001 (everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro.

Gorshtein A, Rubinfeld H, Kendler E, Theodoropoulou M, Cerovac V, Stalla GK, Cohen ZR, Hadani M, Shimon I.

Endocr Relat Cancer. 2009 Sep;16(3):1017-27. doi: 10.1677/ERC-08-0269. Epub 2009 Jun 9.

11.
12.

Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.

Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, Knowles DM, Lane J, Chen-Kiang S.

Cancer Res. 2005 Dec 15;65(24):11345-53.

14.

Time course changes in signaling pathways and protein synthesis in C2C12 myotubes following AMPK activation by AICAR.

Williamson DL, Bolster DR, Kimball SR, Jefferson LS.

Am J Physiol Endocrinol Metab. 2006 Jul;291(1):E80-9.

15.

L-leucine increases [3H]-thymidine incorporation in chicken hepatocytes: involvement of the PKC, PI3K/Akt, ERK1/2, and mTOR signaling pathways.

Lee MY, Jo SD, Lee JH, Han HJ.

J Cell Biochem. 2008 Dec 15;105(6):1410-9. doi: 10.1002/jcb.21959.

PMID:
18980246
16.

Prostaglandin F2α stimulates PI3K/ERK/mTOR signaling and skeletal myotube hypertrophy.

Markworth JF, Cameron-Smith D.

Am J Physiol Cell Physiol. 2011 Mar;300(3):C671-82. doi: 10.1152/ajpcell.00549.2009. Epub 2010 Dec 29.

17.

Impact of resistance loading on myostatin expression and cell cycle regulation in young and older men and women.

Kim JS, Cross JM, Bamman MM.

Am J Physiol Endocrinol Metab. 2005 Jun;288(6):E1110-9. Epub 2005 Jan 11.

18.

Cyclin D1 is required for S phase traversal in bovine tracheal myocytes.

Xiong W, Pestell RG, Watanabe G, Li J, Rosner MR, Hershenson MB.

Am J Physiol. 1997 Jun;272(6 Pt 1):L1205-10.

PMID:
9227524
19.

Signaling pathways initiated by beta-hydroxy-beta-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli.

Eley HL, Russell ST, Baxter JH, Mukerji P, Tisdale MJ.

Am J Physiol Endocrinol Metab. 2007 Oct;293(4):E923-31. Epub 2007 Jul 3.

20.

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

Joshi KS, Rathos MJ, Joshi RD, Sivakumar M, Mascarenhas M, Kamble S, Lal B, Sharma S.

Mol Cancer Ther. 2007 Mar;6(3):918-25.

Supplemental Content

Support Center